Dr Jay Edelberg, Head of the PCSK9 Development and Launch Unit at Sanofi discusses the ongoing clinical trial assessing PCSK9 inhibitors for use in patients with high cholesterol, in our ...

Statins: For statins, the side effects can be surprising. Some people taking these medications have been found to gain weight ...

In Africa, the revenue in the Lipid-Lowering Agents market is projected to reach US$83.04m in 2024. Looking ahead, it is expected to show an annual growth rate (CAGR 2024-2029) of 0.43%.

The projected revenue for the Lipid-Lowering Agents market in Brazil is expected to reach US$143.60m in 2024. It is anticipated that the market will experience an annual growth rate (CAGR 2024 ...

The leading therapeutic classes in 2003 sales were cholesterol-lowering agents, with $13.9 billion ... manufacturer to make the top 10 list. Among the significant patent expirations faced by ...

Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Syndromes (PROVE IT-TIMI 22) Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression ...